3.4. Pd-catalyzed asymmetric allylic substitution using a sugar-based monophosphite ligand library

Abstract. We have synthesized a modular sugar-based phosphite ligand library for the Pd-catalyzed allylic substitution reactions of several substrates. These ligands are derived from D-glucose, D-galactose and D-fructose, which lead to a wide range of sugar backbones, and contain several substituents/configurations in the biaryl moiety, with different steric and electronic properties. Systematic variation of the ligand parameters indicates that the catalytic performance (activities and enantioselectivities) is highly affected by sugar backbone, the configurations at carbon C-3 and C-4 of the ligand backbone and the type of substituents/configurations in the biaryl phosphite moiety.

3.4.1. Introduction

Palladium-catalyzed asymmetric allylic alkylation is a useful synthetic method for the enantioselective formation of C-C bonds.¹ The selection of chiral ligands for highly enantioselective allylic substitution has focussed on the use of bidentate nitrogen and phosphorus donors (both homo- and heterodonors).¹ Less attention has been paid to catalysts containing monodentated ligands in this process. However, in 2000, the groups of RajanBabu and Zhang obtained an enantioselectivity of 94% with catalysts precursors containing monophospholane ligands in the Pd-catalyzed allylic alkylation to *rac*-1,3-diphenyl-3acetoxyprop-1-ene.² Despite this success, few monophosphorus ligands have been applied in the Pd-catalyzed asymmetric allylic substitution.³ This encourages further research into monophosphorous ligands to study their possibilities as a new class of ligands for this process. Recently, a group of less electron-rich phosphorus compounds-biaryl diphosphite ligands-have also demonstrated their potential utility by overcoming the most common limitations of this process, such as

low reaction rates and high substrate specificity.⁴ Therefore, these ligand systems have provided excellent enantioselectivities and activities in different substrate types.⁴

Following our interest in modular π -acceptor ligands⁴ and encouraged by the success of monophosphorous ligands, we report here the design of a library of 30 potential chiral monophosphite ligands **L7-L11a-f** (Figure 1) and screen their use in the palladium allylic substitution reaction of several substrate types. These ligands are derived from natural D-glucose, D-galactose and D-fructose and have the advantage of carbohydrate and phosphite ligands, such as availability at low price from readily available alcohols and facile modular constructions.⁵ In addition they are less sensitive to air than typical phosphines, widely used as ligands in asymmetric catalysis. All these favourable features enable series of chiral ligands to be synthesized and screened in the search for high activity and selectivity. Although carbohydrate-based bidentate ligands have been successfully used in some enantioselective reactions (mainly hydrogenation and allylic alkylation),⁵ few good monodentate chiral ligands have been reported based on carbohydrates.^{2,6}




Figure 1. Carbohydrate-based phosphite ligands L7-L11a-f.

3.4.2. Results and Discussion

3.4.2.1. Ligand design

The sugar-based monophosphite ligands are derived from D-glucose, D-galactose and D-fructose, which lead to a wide range of sugar backbones (L7-L11), and contain several substituents/configurations in the biaryl moiety (**a-f**), with different steric and electronic properties, whose effect on the catalytic perfomance will be studied. Therefore, ligands L7-L11a-f consist of chiral di-*O*-protected either furanoside (ligands L7-L9) or pyranoside (ligands L10 and L11) backbones, which determine their underlying structure, and one hydroxyl group. Several phosphoric acid biaryl esters (**af**) were attached to these basic frameworks (Figure 1).


The influence of the different groups attached to the *ortho-* and *para-*positions of the biphenyl moieties on enantioselectivity was investigated using ligands **L7a-d**, which have the same configuration on the carbon atom C-3. To determine whether there is a cooperative effect between the stereocenters of the ligand backbone and the configuration of the biaryl phosphite moieties, we prepared a series of enantiomerically pure binaphthol-based ligands **L7e-f** and **L8e-f**.

We studied the effects of the stereogenic carbon atom C-3 on enantioselectivity by comparing diastereomeric ligands **L7** and **L8** which have opposite configuration at C-3. The influence of the configuration of carbon atom C-4 in the catalytic performance was studied using ligands **L7** and **L9** which only differ in the configuration at C-4.

The influence of the carbohydrate ring size in the catalytic performance of the Pd-catalysts was studied with ligands **L10**, which have a pyranoside backbone and the same configuration at C-3 than ligand **L7**. Finally, with ligands **L11** we studied how the flexibility of the ligand backbone may affect the catalytic performance. These ligands have a pyranoside backbone as ligands **L10**, but differs from the rest of ligands in a phosphite moiety attached to a primary alcohol, providing a more flexible ligand.

3.4.2.2. Ligand synthesis

Ligands L7-11a- f^7 were efficiently synthesized in one step by reaction of the corresponding sugar alcohols (1-5) with 1 equiv of PCl₃ and subsequent addition of the biaryl alcohols (a-f) in the presence of triethylamine using a series of parallel reactors each equipped with 12 positions (Scheme 1).^{6c} Sugar alcohols 1-5 were easily prepared on a large scale from inexpensive D-(+)-glucose, D-(+)-galactose and D-(-)-fructose, (Scheme 1).




Scheme 1. Synthesis of phosphite ligands **L7-L11a-f**. a) Acetone, I₂, 6 h.⁸ b) PCC, CH₂Cl₂, NaOAc, 16 h.⁹ c) NaBH₄, EtOH, -20 °C to rt overnight.⁹ d) DMF, acetone, Dowex H⁺, reflux 48 h.¹⁰ e) HClO₄, dimethoxypropane, 0 °C, 6 h.¹¹ f) HClO₄, dimethoxypropane, rt, 16 h.¹² g) PCl₃, NEt₃, THF, biaryl alcohol (**a-f**), rt.^{6c}

All the ligands were stable during purification on neutral silica under an atmosphere of argon and isolated in moderate yields as white solids. The elemental analysis were in agreement with the assigned structure. The ¹H, ³¹P and ¹³C NMR spectra were as expected for these C_1 ligands.

3.4.2.3. Allylic alkylation of disubstituted linear substrates

In this section, we report the use of the chiral phosphite ligand library (L7-L11af) in the Pd-catalyzed allylic alkylation (equation 1) of two disubstituted linear substrates with different steric properties: *rac*-1,3-diphenyl-3-acetoxyprop-1-ene S1 and *rac*-1,3-dimethyl-3-acetoxyprop-1-ene S2. In all the cases, the catalysts were generated *in situ* from 0.5 mol % of π -allyl-palladium chloride dimer [PdCl(η^3 -C₃H₅)]₂, the corresponding ligand and a catalytic amount of potassium acetate.



We first investigated the Pd-catalyzed allylic substitution of *rac*-1,3-diphenyl-3acetoxyprop-1-ene **S1**, which is widely used as a model substrate. The effect of the solvent and the ligand-to-palladium ratio were investigated using the catalyst precursor containing ligand **L8b** (Table 1). The results indicated that solvent affected catalytic performance. The optimum trade-off between enantioselectivities and activities was obtained when dichloromethane was used as a solvent (Table 1, entry 4). We next studied the effect of the ligand-to-palladium ratio. Interestingly, we found that activities were best with a ligand-to-palladium ratio of 1, while enanioselectivities were similar (Table 1, entries 4 vs 5).¹³

00		$\frac{0}{(2 - 1)^b}$	% ee ^c
Solvent	Katio L/Fu	76 COIIV (II)	70 66
DMF	1	43 (4)	11 (<i>R</i>)
Toluene	1	9 (8)	19 (<i>R</i>)
THF	1	24 (4)	17 (<i>R</i>)
CH_2Cl_2	1	31 (4)	23 (<i>R</i>)
CH_2Cl_2	2	14 (4)	20 (<i>R</i>)
	Solvent DMF Toluene THF CH ₂ Cl ₂	DMF1Toluene1THF1 CH_2Cl_2 1	Solvent Ratio L/Pd % Conv (h) ^b DMF 1 43 (4) Toluene 1 9 (8) THF 1 24 (4) CH_2Cl_2 1 31 (4)

 Table 1. Pd-catalyzed allylic alkylation of 1,3-diphenyl-3-acetoxyprop

 1-ene S1 using ligands L8b.^a

^a 0.5 mol% [Pd(π -C₃H₅)Cl]₂, room temperature, 30 min; 3 equiv of CH₂(COOMe)₂ and *N*,*O*-bis(trimethylsilyl)acetamide (BSA), a pinch of KOAc, room temperature. ^b Measured by ¹H NMR. Reaction time in minutes shown in parentheses. ^c Determined by HPLC (Chiralcel OD).

Under the optimized conditions, we evaluated the phosphite ligands in the Pdcatalyzed allylic substitution of *rac*-1,3-diphenyl-3-acetoxyprop-1-ene **S1**. The results, which are summarized in Table 2, indicate that the catalytic performance (activities and enantioselectivities) is highly affected by the substituents of the biaryl moieties, the configuration of carbon atoms C-3 and C-4 and the size of the ring of the sugar backbone. In general, activities (TOF's up to 30 mol **6** x (mol Pd x h)⁻¹) and enantioselectivities (ee's up to 41%) were low.

The results using ligands **L7a-f** and **L8a-f** allow us to study the influence of the substituents/configuration of the biaryl moiety on the product outcome (Table 2, entries 1-12). We found that activities were best when binaphthyl phosphite moieties were present, while enantioselectivities were best using ligands **L7d** and **L8d**, which have trimethylsilyl substituents at the *ortho* positions of the biphenyl phosphite moiety (Table 2, entries 4 and 10).

L11a-f. ^a	1		0 0
Entry	Ligand	% Conv (h) ^b	% ee ^c
1	L7a	4 (4)	0
2	L7b	35 (4)	31 (<i>S</i>)
3	L7c	84 (4)	22 (<i>S</i>)
4	L7d	42 (4)	40 (<i>S</i>)
5	L7e	100 (4)	19 (<i>R</i>)
6	L7f	100 (4)	18 (<i>R</i>)
7	L8a	5 (4)	0
8	L8b	31 (4)	23 (<i>R</i>)
9	L8c	81 (4)	20 (<i>R</i>)
10	L8d	53 (4)	41 (<i>R</i>)
11	L8e	99 (4)	28 (R)
12	L8f	87 (4)	4 (<i>S</i>)
13	L9c	100 (4)	15 (<i>S</i>)
14	L10b	10 (4)	15 (<i>S</i>)
15	L10c	8 (4)	14 (<i>S</i>)
16	L11c	82 (4)	11 (<i>R</i>)
17 ^d	L8d	32 (8)	46 (<i>R</i>)

Table 2. Pd-catalyzed allylic alkylation of 1,3-diphenyl-3-acetoxyprop-1-ene S1 in CH_2Cl_2 using ligands L7-L11a-f.^a

^a 0.5 mol% $[Pd(\pi-C_3H_5)Cl]_2$, 1.1 mol% ligand, room temperature, 30min; 3 equiv of $CH_2(COOMe)_2$ and *N*,*O*bis(trimethylsilyl)acetamide (BSA), a pinch of the corresponding base, room temperature. ^b Measured by ¹H NMR. Reaction time in minutes shown in parentheses. ^c Determined by HPLC (Chiralcel OD).^d T=0 °C.

Comparing the results using ligands L7 with L8, that only differ in the configuration at C-3, we observed that this configuration controls the sense of enantioselectivity. Accordingly, ligands L7a-d with an *S* configuration at the C-3 of the ligand backbone, gave the S-6 product, while ligands L8a-d with an *R* configuration at C-3 gave *R*-6 product (Table 2, entries 1-4 *vs* 7-10). Furthermore, comparing ligands L7e-f and L8e-f, we found a cooperative effect between the configuration of the

binaphthyl phosphite moiety and the configuration at C-3, that results in a matched combination for ligand **L8e** (Table 2, entries 5, 6, 11 and 12). The results also showed that ligands **L9** with an *S* configuration at C-4 gave lower enantioselectivities than ligands **L7** with an opposite configuration at this position (Table 2, entries 3 *vs* 13). In addition, ligands **L10** which have a pyranoside backbone provided lower yields and enantioselectivities than their relative furanoside ligands **L7** (Table 2, entries 2 and 3 *vs* 14 and 15). Finally, the most flexible ligand **L11**, which has the phosphite moiety attached to a primary carbon provided the lowest enantioselectivities (Table 2, entry 16).

In addition to the effect of structural parameters on enantioselectivity, the reaction parameters can also be controlled to further improved selectivity. In this case, enantioselectivity was further improved (ee's up to 46%) with ligand **L8d** by lowering the reaction temperature to 0 $^{\circ}$ C (Table 2, entry 17).

We then tested ligands **L7d** and **L8d** (the ones that provided the best results in the alkylation of **S1**) in the allylic alkylation of unhindered linear substrate **S2** (equation 1, R = Me). Unfortunately, activities (up to 43% in 24 hours) and enantioselectivities (32% (*R*) for **L7d** and 34% (*S*) for **L8d**) were low.

3.4.2.4. Allylic alkylation of cyclic substrates

To further study the potential of ligands **L7-L11a-f**, we also tested the best ligands **L7d** and **L8d** in the allylic alkylation of substrate **S3**. As for unhindered substrate **S2**, enantioselectivity in cyclic substrates is difficult to control, mainly because of the presence of less sterically *syn* substituents (equation 2).¹ The results are shown in Table 3. Enantioselectivities up to 38% were obtained (Table 3, entry 2). As observed for substrates **S1** and **S2**, changing the solvent from dichloromethane to other solvents did not increase enantioselectivity (Table 3, entries 2-5).





Table 3. Pd-catalyzed allylic alkylation of *rac*-3-acetoxy-cyclohexene S3 using ligands L7d and L8d.^a

Entry	Ligand	Solvent	% Conv (h) ^b	% ee ^c
1	L7d	CH_2Cl_2	10 (24)	28 (R)
2	L8d	CH_2Cl_2	12 (24)	38 (<i>S</i>)
3	L8d	DMF	52 (24)	21 (<i>S</i>)
4	L8d	Toluene	10 (24)	33 (<i>S</i>)
5	L8d	THF	32 (24)	17 (<i>S</i>)

^a 0.5 mol% [Pd(π -C₃H₅)Cl]₂, 1.1 mol% ligand, room temperature, 30min; 3 equiv of CH₂(COOMe)₂ and *N*,*O*-bis(trimethylsilyl)acetamide (BSA), a pinch of the corresponding base, room temperature. ^b Measured by GC. Reaction time in minutes shown in parentheses. ^c Determined by GC.

3.4.2.5. Allylic substitution of monosubstituted linear substrates

Finally, we also examined the regio- and stereoselective allylic alkylation of 1-(1-naphthyl)allyl acetate **S4** with dimethyl malonate (equation 3). As we previously mentioned, for this substrate, the development of highly regio- and enantioselective Pd-catalysts is still a challenge. 4d,14



The results obtained with the phosphite ligands are summarized in Table 4. Unfortunately, the enantioselectivity (ee's up to 40%) was not high. However, good regioselectivities (regio's up to 80%) has been obtained.¹⁵ The results indicated that if

regioselectivity is to be high, bulky substituents at the *ortho* positions of the biaryl phosphite moiety and a furanoside backbone with an *S* and *R* configuration at C-3 and C-4, respectively, are necessary. However, enantioselectivities were best for furanoside ligand **L9c** with *S* configurations at both C-3 and C-4.

Entry	Ligand	% Conv (h) ^b	9/10 ^b	% ee ^c
1	L7a	100 (6)	15/85	0
2	L7b	100 (6)	80/20	7 (<i>R</i>)
3	L7c	100 (6)	75/25	9(<i>R</i>)
4	L7d	100 (6)	80/20	18 (<i>R</i>)
5	L7e	100 (6)	20/80	0
6	L7f	100 (6)	35/65	17 (<i>S</i>)
7	L8a	100 (6)	15/85	0
8	L8b	100 (6)	75/25	10 (<i>R</i>)
9	L8c	100 (6)	70/30	21 (<i>R</i>)
10	L8d	100 (6)	60/40	<5 (<i>R</i>)
11	L8e	100 (6)	25/75	3 (<i>S</i>)
12	L8f	100 (6)	20/80	18 (<i>R</i>)
13	L9c	100 (6)	45/55	40 (<i>R</i>)
14	L10b	100 (6)	35/65	<5 (<i>S</i>)
15	L10c	100 (6)	30/70	<5 (<i>R</i>)
16	L11c	100 (6)	70/30	25 (R)

Table 4. Pd-catalyzed allylic alkylation of **S4** in CH₂Cl₂ using ligands **L7-L11a-f**.^a

^a 0.5 mol% [Pd(π -C₃H₅)Cl]₂, 2.2 mol% ligand, room temperature, 30 min; 3 equiv of CH₂(COOMe)₂ and *N*,*O*-bis(trimethylsilyl)acetamide (BSA), a pinch of the corresponding base, room temperature. ^b Measured by ¹H NMR. Reaction time in minutes shown in parentheses. ^c Determined by HPLC (Chiralcel OJ).

3.4.3. Conclusions

A library of readily available monophosphite ligands has been synthesized and applied in the asymmetric Pd-catalyzed allylic alkylation of several substrates with

different electronic and steric properties. By carefully designing this library we were able to systematically investigate the effect of varying the sugar backbone, the configurations at carbon C-3 and C-4 of the ligand backbone and the type of substituents/configurations in the biaryl phosphite moiety. In general, the catalytic performance (activities and enantioselectivities) is highly affected by these ligand parameters. Therefore for substrates S1-S3 enantioselectivies were best with ligands L7d and L8d, while for substrate S4 ligand L9c provided the best ee's.

3.4.4. Experimental section

3.4.4.1. General comments

All syntheses were performed by using standard Schlenk techniques under argon atmosphere. Solvents were purified by standard procedures. Compounds 1-5 were prepared by previously described methods.⁸⁻¹² Ligands L7a, L7c, L7e-f, L8e-f and L10e-f have been previously synthesized.⁷ Racemic substrates S1-S4 were prepared as previously reported.¹⁶⁻¹⁸ All other reagents were used as commercially available. ¹H, ¹³C{¹H} and ³¹P{¹H} NMR spectra were recorded on a Varian Gemini 400 MHz spectrometer. The chemical shifts are referenced to tetramethylsilane (${}^{1}H$ and ${}^{13}C$) as internal standard or H₃PO₄ (³¹P) as external standard. The ¹H and ¹³C NMR spectral assignments were determined by ¹H-¹H and ¹H-¹³C correlation spectra.

3.4.4.2. Synthesis of the chiral monophosphite ligands

1,2:5,6-di-O-isopropylidene-3-O-((3,3'-di-tert-butyl-5,5'-dimethoxy-1,1'-biphenyl-2,2'*diyl)phosphite)-a-D-glucofuranose* (L7b)

To a stirred solution of 1,2:5,6-di-O-isopropylidene- α -D-glucofuranose 1 (390 mg, 1.5 mmol) in THF (5 mL) was slowly added PCl_3 (132 μ l, 1.5 mmol) as a solution in THF (4 mL) and the resulting mixture was stirred for 1 h at room temperature. The

reaction mixture was then cooled to -10 °C and NEt₃ (1.07 mL, 4.5 mmol) was slowly added. The reaction mixture was allowed to warm to room temperature, maintained under these conditions for 0.25 h, and then cooled to 0 °C. Solid 3,3'-di-tert-butyl-5,5'dimethoxy-1,1'-biphenyl-2,2'-diol (0.54 g, 1.5 mmol) was added and the resulting mixture was allowed to warm to room temperature and stirred overnight. Diethyl ether was added and then the solid was removed by filtration through a pad of celite, the solvent was removed in *vacuo* and the residue was purified by flash chromatography (eluent CH₂Cl₂ Rf: 0.32) to produce 100 mg (11%) of a white solid. ³¹P NMR (C_6D_6) $\delta = 145.2$ (s). ¹H NMR (C₆D₆) $\delta = 1.03$ (s, 3H, CH₃), 1.26 (s, 3H, CH₃), 1.34 (s, 3H, CH₃), 1.39 (s, 3H, CH₃), 1.49 (s, 18H, CH₃, ^tBu), 3.31 (s, 6H, OMe), 4.01 (dd, 1H, H- $6^{2}, {}^{2}J_{6^{2}-6}=8.4 \text{ Hz}, {}^{2}J_{6^{2}-5}=6.0 \text{ Hz}$, 4.10 (dd, 1H, H-6, ${}^{2}J_{6-6}=8.4 \text{ Hz}, {}^{3}J_{6-5}=5.2 \text{ Hz}$), 4.27 (m, 1H, H-2), 4.44 (dd, 1H, H-4, ${}^{3}J_{4-3}$ =2.4 Hz, ${}^{3}J_{4-5}$ =8.0 Hz), 4.57 (m, 1H, H-5), 5.20 (dd, 1H, H-3, ${}^{3}J_{3-4}=2.8$ Hz, ${}^{2}J_{3-P}=8.0$ Hz), 5.83 (d, 1H, H-1, ${}^{3}J_{1-2}=3.6$ Hz), 6.66 (m, 1H, CH=), 6.72 (m, 1H, CH=), 7.14 (m, 2H, CH=). ¹³C NMR (C_6D_6) δ = 25.8 (CH₃), 26.4 (CH₃), 27.2 (CH₃), 27.5 (CH₃), 31.4 (CH₃,^tBu), 31.5 (CH₃,^tBu), 31.6 (CH₃,^tBu), 36.2 (C ^tBu), 36.3 (C ^tBu), 55.4 (d, OCH₃, J_{c-p}=3.7 Hz), 68.0 (C-6), 73.4 (C-5), 77.6 (C-3), 81.9 (d, C-4, J_{c-p}=4.6 Hz), 85.0 (C-2), 106.1 (C-1), 112.2 (C), 113.7 (CH=), 114.0 (CH=), 115.2 (CH=), 143.1 (C), 154.1 (C), 155.6 (C), 157.0 (C). Anal. calcd (%) for C₃₄H₄₇O₁₀P: C 63.15, H 7.33; found: C 63.30, H 7.42.

1,2:5,6-di-O-isopropylidene-3-O-((3,3'-di-trimethylsilyl-1,1'-biphenyl-2,2'-diyl) phosphite)-α-D-glucofuranose (**L7d**)

Treatment of 3,3'-di-trimethylsilyl-1,1'-biphenyl-2,2'-diol (0.49 g, 1.5 mmol) and **1** (390 mg, 1.5 mmol), as described for compound **L7b**, afforded phosphite **L7d**, which was purified by flash chromatography (eluent CH₂Cl₂, Rf: 0.61) to produce 210 mg (22%) of a white solid. ³¹P NMR (C₆D₆) δ = 146.0 (s). ¹H NMR (C₆D₆) δ = 0.39 (s, 9H, CH₃-Si), 0.40 (s, 9H, CH₃-Si), 0.98 (s, 3H, CH₃), 1.26 (s, 3H, CH₃), 1.30 (s, 3H, CH₃), 1.41 (s, 3H, CH₃), 4.00 (dd, 1H, H-6', ²J_{6'-6}= 8.4 Hz, ³J_{6'-5}= 6.0 Hz), 4.10 (m, 2H, H-6, H-2), 4.44 (m, 1H, H-4), 4.56 (m, 1H, H-5), 5.13 (m, 1H, H-3), 5.85 (d, 1H, H-1,

 ${}^{3}J_{1\cdot2}$ =4.0 Hz), 7.02 (m, 2H, CH=), 7.16 (m, 2H, CH=), 7.38 (m, 2H, CH=). 13 C NMR (C₆D₆) δ = 0.4 (CH₃-Si), 25.8 (CH₃), 26.4 (CH₃), 27.1 (CH₃), 27.5 (CH₃), 67.9 (C-6), 73.4 (C-5), 77.4 (C-3), 81.8 (d, C-4, J_{c-p} =4.6 Hz), 84.9 (C-2), 106.0 (C-1), 109.8 (C), 112.2 (C), 125.5 (CH=), 125.6 (CH=), 130.8 (C), 132.1 (C), 133.1 (CH=), 133.2 (CH=), 135.7 (CH=), 135.8 (CH=). Anal. calcd (%) for C₃₀H₄₃O₈PSi₂: C 58.23, H 7.00; found: C 58.43, H 6.98.

1,2:5,6-di-O-isopropylidene-3-O-((1,1'-biphenyl-2,2'-diyl)phosphite)-α-D-allofuranose (**L8a**)

Treatment of 1,1'-biphenyl-2,2'-diol (0.28 g, 1.5 mmol) and **2** (390 mg, 1.5 mmol), as described for compound **L7b**, afforded phosphite **L8a**, which was purified by flash chromatography (eluent CH₂Cl₂, Rf: 0.45) to produce 150 mg (22%) of a white solid. ³¹P NMR (C₆D₆) δ =139.5 (s). ¹H NMR (C₆D₆) δ = 1.16 (s, 3H, CH₃), 1.31 (s, 3H, CH₃), 1.49 (s, 3H, CH₃), 1.50 (s, 3H, CH₃), 3.78 (m, 1H, H-6'), 3.93 (m, 1H, H-6), 4.11 (dd, 1H, H-2, ³J_{2.3}=4.2 Hz, ³J_{2.1}=3.6 Hz), 4.17 (m, 1H, H-5), 4.34 (m, 1H, H-4), 4.48 (m, 1H, H-3), 5.33 (d, 1H, H-1, ³J_{1.2}=3.6 Hz), 6.94-7.07 (m, 4H, CH=), 7.20 (m, 2H, CH=), 7.37 (m, 2H, CH=).¹³C NMR (C₆D₆) δ = 25.9 (CH₃), 27.1 (CH₃), 27.2 (CH₃), 27.3 (CH₃), 66.5 (C-6), 75.1 (C-3), 76.5 (C-5), 79.4 (C-4), 80.0 (C-2), 104.7 (C-1), 110.6 (CMe₂) 117.4 (CH=), 122.0 (C), 122.6 (C), 123.0 (CH=), 123.1 (CH=), 125.7 (CH=), 127.8 (CH=), 129.7 (CH=), 130.0 (CH=), 130.3 (C), 130.5 (CH=), 132.3 (CH=), 132.7 (C). Anal. calcd (%) for C₂₄H₂₇O₈P: C 60.76, H 5.74; found: C 60.82, H 5.89.

1,2:5,6-di-O-isopropylidene-3-O-((3,3'-di-tert-butyl-5,5'-dimethoxy-1,1'-biphenyl-2,2'-diyl)phosphite)-α-D-allofuranose (L8b)

Treatment of 3,3'-di-*tert*-butyl-5,5'-dimethoxy-1,1'-biphenyl-2,2'-diol (0.54 g, 1.5 mmol) and **2** (390 mg, 1.5 mmol), as described for compound **L7b**, afforded phosphite **L8b**, which was purified by flash chromatography (eluent CH_2Cl_2 , Rf: 0.30) to produce 180 mg (19%) of a white solid. ³¹P NMR (C₆D₆) δ =144.1 (s). ¹H NMR (C₆D₆) δ = 1.14 (s, 3H, CH₃), 1.29 (s, 3H, CH₃), 1.42 (s, 3H, CH₃), 1.49 (s, 3H, CH₃), 1.54 (s, 9H, CH₃,

^{*t*}Bu), 1.56 (s, 9H, CH₃, ^{*t*}Bu), 3.33 (s, 3H, OMe), 3.36 (s, 3H, OMe), 3.76 (m, 1H, H-6^{*t*}), 3.82 (m, 1H, H-6), 4.03 (m, 1H, H-2), 4.17 (m, 1H, H-5), 4.41 (m, 1H, H-4), 4.46 (m, 1H, H-3), 5.42 (d, 1H, H-1, ${}^{3}J_{1-2}$ =3.6 Hz), 6.71 (m, 2H, CH=), 7.15 (m, 2H, CH=). 13 C NMR (C₆D₆) δ = 26.1 (CH₃), 27.1 (CH₃), 27.2 (CH₃), 27.4 (CH₃), 31.6 (CH₃, ^{*t*}Bu), 35.9 (C), 36.0 (C), 55.4 (OCH₃), 55.5 (OCH₃), 66.0 (C-6), 75.3 (C-3), 76.7 (C-5), 79.4 (d, C-4, *J*_{c-p}=3.1 Hz), 79.6 (C-2), 104.8 (C-1), 110.1 (C), 113.4 (CH=), 113.6 (C), 114.0 (CH=), 115.0 (CH=), 142.8 (C), 143.7 (C), 143.8 (C), 156.9 (C). Anal. calcd (%) for C₃₄H₄₇O₁₀P: C 63.15, H 7.33; found: C 63.08, H 7.42.

1,2:5,6-di-O-isopropylidene-3-O-((3,3'-5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'-diyl) phosphite)-α-D-allofuranose (**L8c**)

Treatment of 3,3';5,5'-tetra-*tert*-butyl-1,1'-biphenyl-2,2'-diol (0.62 g, 1.5 mmol) and **2** (390 mg, 1.5 mmol), as described for compound **L7b**, afforded phosphite **L8c**, which was purified by flash chromatography (eluent CH₂Cl₂, Rf: 0.41) to produce 110 mg (12%) of a white solid. ³¹P NMR (CDCl₃) δ =143.2 (s). ¹H NMR (CDCl₃) δ = 1.29 (s, 3H, CH₃), 1.31 (s, 3H, CH₃), 1.33 (s, 3H, CH₃), 1.35 (s, 18H, CH₃, 'Bu), 1.48 (s, 9H, CH₃, 'Bu), 1.49 (s, 9H, CH₃, 'Bu), 1.54 (s, 3H, CH₃), 3.62 (m, 1H, H-6'), 3.77 (m, 1H, H-6), 3.95 (m, 1H, H-2), 4.09 (m, 1H, H-4), 4.14 (m, 1H, H-5), 4.33 (m, 1H, H-3), 5.54 (d, 1H, H-1, ³*J*₁₋₂=3.2 Hz), 7.12 (m, 1H, CH=), 7.18 (m, 1H, CH=), 7.43 (m, 2H, CH=). ¹³C NMR (CDCl₃) δ = 25.6 (CH₃), 26.4 (CH₃), 26.6 (CH₃), 26.7 (CH₃), 31.1 (CH₃,'Bu), 31.2 (CH₃,'Bu), 31.4 (CH₃,'Bu), 31.5 (CH₃,'Bu), 34.6 (C), 34.7 (C), 35.4 (C), 65.1 (C-6), 73.5 (C-3), 75.3 (C-5), 77.7 (d, C-4, *J*_{c-p}=3.9 Hz), 78.5 (C-2), 103.6 (C-1), 109.6 (C), 113.1 (C), 124.0 (CH=), 124.2 (CH=), 125.3 (CH=), 126.2 (CH=), 126.8 (CH=), 128.2 (CH=), 129.0 (CH=), 140.2 (C), 140.4 (C), 133.5 (C), 133.7 (C), 146.6 (C), 146.7 (C). Anal. caled (%) for C4₄0H₅₉O₈P: C 68.74, H 8.51; found: C 68.89, H 8.63.

1,2:5,6-di-O-isopropylidene-3-O-((3,3'-di-trimethylsilyl-1,1'-biphenyl-2,2'-diyl) phosphite)- α -D-allofuranose (L8d)

Treatment of 3,3'-di-trimethylsilyl-1,1'-biphenyl-2,2'-diol (0.49 g, 1.5 mmol) and **2** (390 mg, 1.5 mmol), as described for compound **L7b**, afforded phosphite **L8d**, which was purified by flash chromatography (eluent CH₂Cl₂, Rf: 0.68) to produce 180 mg (20%) of a white solid. ³¹P NMR (C₆D₆) δ =143.4 (s). ¹H NMR (C₆D₆) δ = 0.43 (s, 9H, CH₃-Si), 0.45 (s, 9H, CH₃-Si), 1.11 (s, 3H, CH₃), 1.30 (s, 3H, CH₃), 1.43 (s, 3H, CH₃), 1.47 (s, 3H, CH₃), 3.66 (m, 2H, H-6', H-2), 3.76 (m, 1H, H-6), 4.12 (m, 1H, H-5), 4.37 (m, 2H, H-3, H-4), 5.33 (d, 1H, H-1, ³J₁₋₂=3.6 Hz), 7.02 (m, 2H, CH=), 7.18 (m, 2H, CH=), 7.40 (m, 2H, CH=). ¹³C NMR (C₆D₆) δ = -0.1 (CH₃-Si), 25.7 (CH₃), 26.7 (CH₃), 26.9 (CH₃), 65.4 (C-6), 74.6 (d, C-4, J_{c-p}=8.4 Hz), 76.4 (C-5), 78.5 (d, C-3, J_{c-p}=3.0 Hz), 78.9 (C-2), 104.2 (C-1), 113.2 (C), 124.9 (CH=), 125.0 (CH=), 130.3 (C), 130.5 (C), 132.2 (CH=),132.8 (CH=),135.1 (CH=),135.3 (CH=). Anal. calcd (%) for C₃₀H₄₃O₈PSi₂: C 58.23, H 7.00; found: C 58.84, H 7.17.

1,2:5,6-di-O-isopropylidene-3-O-((3,3'-5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'-diyl) phosphite)- α -D-galactofuranose (**L9c**)

Treatment of 3,3';5,5'-tetra-*tert*-butyl-1,1'-biphenyl-2,2'-diol (0.62 g, 0.5 mmol) and **3** (390 mg, 0.5 mmol), as described for compound **L7b**, afforded phosphite **L9c**, which was purified by flash chromatography (eluent CH₂Cl₂, Rf: 0.55) to produce 80 mg (23%) of a white solid. ³¹P NMR (CDCl₃) δ =137.6 (s). ¹H NMR (CDCl₃) δ = 1.28 (s, 3H, CH₃), 1.31 (s, 3H, CH₃), 1.34 (s, 18H, CH₃, 'Bu), 1.37 (s, 3H, CH₃), 1.45 (s, 3H, CH₃), 1.47 (s, 18H, CH₃, 'Bu), 3.47 (m, 1H, H-6'), 3.91 (m, 2H, H-5, H-6), 4.19 (d, 1H, H-4, ³J₄₋₃=8 Hz), 4.27 (dd, 1H, H-2, ³J₂₋₁=5.2 Hz, J_{2-P}=4.8 Hz), 4.55 (dd, 1H, H-3, ³J₃, 4=8 Hz, J_{3-P}=5.2 Hz), 5.47 (d, 1H, H-2, ²J₂₋₁=5.2 Hz), 7.14 (m, 2H, CH=), 7.41 (m, 2H, CH=), ¹³C NMR (CDCl₃) δ = 24.6 (CH₃), 25.1 (CH₃), 26.2 (CH₃), 26.3 (CH₃), 31.2 (CH₃,'Bu), 31.3 (CH₃,'Bu), 31.7 (CH₃,'Bu), 31.8 (CH₃,'Bu), 34.8 (C), 35.5 (C), 35.6 (C), 62.9 (d, C-6, J_{c-P}=2.2 Hz), 67.2 (d, C-5, J_{c-P}=2.3 Hz), 70.6 (C-4), 70.7 (C-2), 70.8 (C-3), 96.4 (C-1), 108.8 (C), 109.6 (C), 124.4 (CH=), 124.4 (CH=), 125.5 (CH=), 126.7 (CH=), 128.5 (C), 129.2 (C), 129.3 (C), 133.3 (C), 138.3 (C), 140.0 (C), 140.1 (C),

146.5 (C), 146.6 (C). Anal. calcd (%) for C₄₀H₅₉O₈P: C 68.74, H 8.51; found: C 68.98, H 8.62.

2,3:5,6-di-O-isopropylidene-4-O-((3,3'-di-tert-butyl-5,5'-dimethoxy-1,1'-biphenyl-2,2'diyl)phosphite)- β -D-fructopyranose (L10b)

Treatment of 3,3'-di-*tert*-butyl-5,5'-dimethoxy-1,1'-biphenyl-2,2'-diol (0.54 g, 1.5 mmol) and **4** (390 mg, 1.5 mmol), as described for compound **L7b**, afforded phosphite **L10b**, which was purified by flash chromatography (eluent CH₂Cl₂, Rf: 0.55) to produce 270 mg (29%) of a white solid. ³¹P NMR (C₆D₆) δ =149.8 (s). ¹H NMR (C₆D₆) δ = 1.13 (s, 3H, CH₃), 1.24 (s, 3H, CH₃), 1.40 (s, 9H, CH₃, 'Bu), 1.45 (s, 3H, CH₃), 1.60 (s, 12H, , CH₃, CH₃ 'Bu), 3.32 (s, 3H, OMe), 3.33 (s, 3H, OMe), 3.80 (m, 1H, H-2), 3.94 (m, 2H, H-1, H-1'), 4.15 (d, 1H, H-6', ²J_{6'-6}=11.2 Hz), 4.48 (m, 1H, H-3), 4.56 (m, 1H, H-4), 4.65 (d, 1H, H-6, ²J₆₋₆=11.6 Hz), 6.68 (m, 2H, CH=), 7.14 (m, 2H, CH=). ¹³C NMR (C₆D₆) δ = 26.1 (CH₃), 26.8 (CH₃), 27.8 (CH₃), 28.9 (CH₃), 31.3 (CH₃,'Bu), 31.4 (CH₃,'Bu), 31.9 (CH₃,'Bu), 35.8 (C), 36.1 (C), 55.4 (OCH₃), 55.5 (OCH₃), 60.7 (C-1), 71.8 (C-6), 72.9 (d, C-4, J_{c-p}=9.2 Hz), 74.8 (C-2), 77.2 (C-3), 104.9 (C-5), 109.9 (CMe₂), 112.9 (CMe₂), 113.5 (CH=), 113.7 (CH=), 115.1 (CH=), 115.3 (CH=), 126.0 (C), 129.6 (C), 134.2 (C), 135.6 (C), 140.0 (C), 143.1 (C), 156.6 (C), 157.0 (C). Anal. calcd (%) for C₃₄H₄₇O₁₀P: C 63.15, H 7.33; found: C 63.44, H 7.51.

2,3:5,6-di-O-isopropylidene-4-O-((3,3'-5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'-diyl) phosphite)-β-D-fructopyranose (L10c)

Treatment of 3,3';5,5'-tetra-*tert*-butyl-1,1'-biphenyl-2,2'-diol (0.62 g, 1.5 mmol) and **4** (390 mg, 1.5 mmol), as described for compound **L7b**, afforded phosphite **L10c**, which was purified by flash chromatography (eluent CH₂Cl₂, Rf: 0.43) to produce 290 mg (28%) of a white solid. ³¹P NMR (C₆D₆) δ =151.7 (s). ¹H NMR (C₆D₆) δ = 1.05 (s, 3H, CH₃), 1.24 (s, 3H, CH₃), 1.27 (s, 9H, CH₃, ^{*t*}Bu), 1.28 (s, 9H, CH₃, ^{*t*}Bu), 1.46 (s, 9H, CH₃, ^{*t*}Bu), 1.60 (s, 3H, CH₃), 1.64 (s, 12H, CH₃, CH₃), 3.80 (m, 1H, H-2), 3.94 (m, 2H, H-1, H-1'), 4.12 (d, 1H, H-6', ²J_{6'.6}=9.6 Hz), 4.50 (m, 1H, H-3), 4.54 (m, 1H, H-4),

5.58 (d, 1H, H-6, ${}^{2}J_{6-6}$ =9.6 Hz), 7.28 (m, 1H, CH=), 7.33 (m, 1H, CH=), 7.55 (m, 2H, CH=). 13 C NMR (C₆D₆) δ = 26.2 (CH₃), 26.8 (CH₃), 28.0 (CH₃), 29.0 (CH₃), 31.5 (CH₃, 'Bu), 31.6 (CH₃, 'Bu), 31.9 (CH₃, 'Bu), 32.0 (CH₃, 'Bu), 32.1 (CH₃, 'Bu), 34.9 (C), 35.0 (C), 35.9 (C), 36.1 (C), 60.6 (C-1), 71.8 (C-6), 72.8 (d, C-4, J_{c-p} =8.3 Hz), 74.8 (C-2), 77.2 (C-3), 104.9 (C-5), 109.9 (CMe₂), 112.9 (CMe₂), 124.5 (CH=), 124.9 (CH=), 126.0 (C), 127.3 (CH=), 127.6 (CH=), 133.7 (C), 134.9 (C), 138.2 (C), 140.9 (C), 141.0 (C), 146.8 (C), 147.3 (C). Anal. calcd (%) for C₄₀H₅₉O₈P: C 68.74, H 8.51; found: C 68.69, H 8.62.

2,3:4,5-di-O-isopropylidene-6-O-((3,3'-5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'-diyl) phosphite)-β-D-fructopyranose (L11c)

Treatment of 3,3';5,5'-tetra-*tert*-butyl-1,1'-biphenyl-2,2'-diol (0.62 g, 1.5 mmol) and **5** (390 mg, 1.5 mmol), as described for compound **L7b**, afforded phosphite **L11c**, which was purified by flash chromatography (eluent Toluene/NEt₃ (100:1)). Rf: 0.55) to produce 140 mg (15%) of a white solid. ³¹P NMR (C_6D_6) δ =135.9 (s). ¹H NMR (C_6D_6) δ =0.70 (s, 3H, CH₃), 0.83 (s, 9H, CH₃, 'Bu), 0.86 (s, 9H, CH₃, 'Bu), 0.95 (s, 3H, CH₃), 0.97 (s, 3H, CH₃), 1.02 (s, 3H, CH₃), 1.20 (s, 9H, CH₃, 'Bu), 1.21 (s, 9H, CH₃, 'Bu), 3.14 (d, 1H, H-6', ¹*J*_{6'-6}=16.8 Hz), 3.31 (m, 2H, H-6, H-4), 3.60 (m, 1H, H-1'), 3.94 (m, 1H, H-1), 4.00 (dd, 1H, H-3, ³*J*₃₋₂=14.0 Hz, ³*J*₃₋₄=3.6 Hz), 4.18 (d, 1H, H-2, ²*J*₂. ¹=3.6 Hz), 6.80 (d, 1H, CH=), 6.90 (d, 2H, CH=), 7.16 (m, 1H, CH=). ¹³C NMR (C₆D₆) δ = 24.7 (CH₃), 26.1 (CH₃), 26.6 (CH₃), 27.1 (CH₃), 31.5 (CH₃, 'Bu), 31.6 (CH₃, 'Bu), 31.9 (CH₃, 'Bu), 32.0 (CH₃, 'Bu), 34.9 (C), 35.0 (C), 36.0 (C), 61.8 (C-6), 64.9 (C-1), 70.4 (C-2), 71.0 (C-3), 71.8 (C-4), 102.9 (C-5), 109.0 (CMe₂), 109.3 (CMe₂), 124.7 (CH=), 124.8 (CH=), 126.0 (C), 127.3 (CH=), 128.6 (CH=), 128.9 (C), 129.6 (C), 133.9 (C), 140.6 (C), 140.8 (C), 147.1 (C), 147.3 (C). Anal. calcd (%) for C₄₀H₅₉O₈P: C 68.74, H 8.51; found: C 68.99, H 8.71.

3.4.4.3. Typical procedure of allylic alkylation of substrates S1-S3

A degassed solution of $[Pd(\pi-C_3H_5)Cl]_2$ (0.9 mg, 0.0025 mmol) and the corresponding phosphite-phosphoroamidite (0.0055 mmol) in THF (0.5 mL) was stirred for 30 min. Subsequently, a solution of corresponding substrate (0.5 mmol) in THF (1.5 mL), dimethyl malonate (171 µL, 1.5 mmol), *N*,*O*-bis(trimethylsilyl)-acetamide (370 µL, 1.5 mmol) and a pinch of KOAc were added. The reaction mixture was stirred at room temperature. After the desired reaction time, the reaction mixture was diluted with Et₂O (5 mL) and a saturated NH₄Cl (aq) (25 mL) was added. The mixture was extracted with Et₂O (3 x 10 mL) and the extract dried over MgSO₄. For substrate **S1**, conversion was measured by ¹H-NMR and enantiomeric excess was determined by HPLC (Chiralcel-OD, 0.5% 2-propanol/hexane, flow 0.5 mL/min).¹⁹ For substrates **S2** and **S3**, conversion and enantiomeric excess were determined by GC using a FS-Cyclodex β -I/P 25 m column.²⁰

3.4.4.4. Typical procedure of allylic alkylation of monosubstituted linear substrates S4

A degassed solution of $[Pd(\pi-C_3H_5)Cl]_2$ (1.8 mg, 0.005 mmol) and the corresponding phosphite-phosphoroamidite ligand (0.011 mmol) in dichloromethane (0.5 mL) was stirred for 30 min. Subsequently, a solution of substrate (0.5 mmol) in dichloromethane (1.5 mL), dimethyl malonate (171 µL, 1.5 mmol), *N,O*-bis(trimethylsilyl)-acetamide (370 µL, 1.5 mmol) and a pinch of KOAc were added. The reaction mixture was stirred at room temperature. After the desired reaction time, the reaction mixture was extracted with Et₂O (5 mL) and a saturated NH₄Cl (aq) (25 mL) was added. The mixture was extracted with Et₂O (3 x 10 mL) and the extract dried over MgSO₄. Solvent was removed and conversion and regioselectivity were measured by ¹H-NMR. To determine the ee by HPLC (Chiralcel-OJ, 3% 2-propanol/hexane, flow 0.7

mL/min), a sample was filtered over basic alumina using dichloromethane as the eluent.²¹

3.4.5. Acknowledgements

We thank the Spanish Government (Consolider Ingenio CSD2006-0003, CTQ2004-04412/BQU and Ramon y Cajal fellowship to O.P.) and the Generalitat de Catalunya (2005SGR007777 and Distinction to M.D.) for financial support.

3.4.6. References

¹ For recent reviews, see: a) Tsuji, J. Palladium Reagents and Catalysis, Innovations in Organic Synthesis; Wiley: New York, 1995. b) Trost, B. M.; van Vranken, D. L. *Chem. Rev.* **1996**, *96*, 395. c) Johannsen, M.; Jorgensen, K. A. *Chem. Rev.* **1998**, *98*, 1689. d) Pfaltz, A.; Lautens, M. In *Comprehensive Asymmetric Catalysis*; Jacobsen, E. N.; Pfaltz, A.; Yamamoto, H., Eds.; Springer-Verlag: Berlin, 1999; Vol. 2, Chapter 24. e) Trost, B. M.; Crawley, M. L. *Chem. Rev.* **2003**, *103*, 2921.

² a) Yan, Y. Y.; RajanBabu, T. V. *Org. Lett.* **2000**, *2*, 199. b) Zhang, X. WO Patent 03/040149 A2, **2003**.

³ a) Mikhel, I. S.; Bernardinelli, G.; Alexakis, A. *Inorg. Chim. Acta* **2006**, *359*, 1826. b) Gavrilov, K. N.; Tsarev, V. N.; Lyubomov, S. E.; Shiryaev, A. A.; Zhelog, S. V.; Bondareg, O. G.; Danankov, V. A.; Kabro, A. A.; Moiseev, S. K.; Kalinin, V. N. *Mendeleev Commun.* **2003**, 134. c) Tsarev, V. N.; Lyubomov, S. E.; Shiryaev, A. A.; Zhelog, S. V.; Bondareg, O. G.; Danankov, V. A.; Kabro, A. A.; Moiseev, S. K.; Kalinin, V. N.; Gavrilov, K. N. *Eur. J. Org. Chem.* **2004**, 2214.

⁴ a) Diéguez, M.; Jansat, S.; Gomez, M.; Ruiz, A.; Muller, G.; Claver, C. Chem. Commun. 2001, 1132. b) Diéguez, M.; Pàmies, O.; Claver, C. Adv. Synth. Catal. 2005, 347, 1257. c) Diéguez, M.; Pàmies, O.; Claver, C. J. Org. Chem. 2005, 70, 3363. d)
Pàmies, O.; Diéguez, M.; Claver, C. J. Am. Chem. Soc. 2005, 127, 3646. e) Mata, Y.;

Diéguez, M.; Pàmies, O.; Claver, C. Adv. Synth. Catal. 2005, 347, 1943. f) Raluy, E.;
Claver, C.; Pàmies, O.; Diéguez, M. Org. Lett. 2007, 9, 49. g) Diéguez, M.; Pàmies,
O.; Claver, C. Adv. Synth. Catal. 2007, 349, 836.

⁵ See for instance: a) Diéguez, M.; Pàmies, O.; Claver, C. Chem. Rev. 2004, 104, 3189.
b) Diéguez, M.; Pàmies, O.; Ruiz, A.; Díaz, Y.; Castillón, S.; Claver, C. Coord. Chem. Rev. 2004, 248, 2165. c) Diéguez, M.; Ruiz, A.; Claver, C. Dalton Trans. 2003, 2957.
d) Pàmies, O.; Diéguez, M.; Ruiz, A.; Claver, C. Chemistry Today 2004, 12. e) Diéguez, M.; Pàmies, O.; Ruiz, A.; Claver, C. in Methodologies in Asymmetric Catalysis (Ed. Malhotra, S. V.); American Chemical Society, Washington DC, 2004. f) Diéguez, M.; Pàmies, O.; Claver, C. Tetrahedron: Asymmetry 2004, 15, 2113. g) Diéguez, M.; Claver, C.; Pàmies, O. Eur. J. Org. Chem. in press.

⁶ See for instance: a) Reetz, M. T.; Mehler, G. Angew. Chem. Int. Ed. 2000, 39, 3889.
b) Reetz, M. T.; Goossen, L. J.; Meiswinkel, A.; Paetzold, J.; Jense, J. F. Org. Lett.
2003, 5, 3099. c) Huang, H.; Zheng, Z.; Luo, H.; Bai, C.; Hu, X.; Chen, H. Org. Lett.
2003, 5, 4137. d) Huang, H.; Liu, X.; Chen, S.; Chen, H.; Zheng, Z. Tetrahedron: Asymmetry 2004, 15, 2011. e) Huang, H.; Liu, X.; Chen, H.; Zheng, Z. Tetrahedron: Asymmetry 2005, 16, 693.

⁷ Ligands L7a, L7c, L7e-f, L8e-f and L10e-f have been previously synthesized, see: a)
Suárez, A.; Pizzano, A.; Fernández, I.; Khiar, N. *Tetrahedron: Asymmetry* 2001, *12*, 633 and refs. 5b-c.

⁸ Kartha, K. P. R. *Tetrahedron Lett.* **1986**, *27*, 3415.

⁹ Hollenberg, D. H.; klein, R. S.; Fox, J. J. Carbohyd. Res. 1978, 67, 491.

¹⁰ Wang, H.; Ning, J. J. Org. Chem. 2003, 68, 2521.

¹¹ Tu, Y.; Frohn, M.; Wang, Z.-X.; Shi, Y. in *Organic Synthesis* (Ed. Wolf, S.), Organic Syntheses, 2003, p. 1.

¹² Beksan, E.; Schieberle, P.; Robert, F.; Blank, I.; Fay, L. B.; Schlichtherle-Cerny, H.; Hofmann, T. J. Agric. Food Chem. 2003, 51, 5428.

¹³ Similar behavior has been observed using monophosphoroamidite ligands, see ref.3a.

¹⁴ For recent successful applications of Pd-catalysts, see: a) You, S. -L.; Zhu, X. –Z.;
Luo, Y.-M.; Hou, X.-L.; Dai, L.-X. J. Am. Chem. Soc. 2001, 123, 7471; b) Hilgraf, R.;
Pfaltz, A. Synlett 1999, 1814. c) Prétôt, R.; Pfaltz, A. Angew. Chem. Int. Ed. 1998, 37, 323

¹⁵ This contrasts with the preferentially formation of the linear isomer **5** observed using monophosphoroamidite ligands, see ref. 3a.

- ¹⁶ Auburn, P. R.; Mackenzie, P. B.; Bosnich B. J. Am. Chem. Soc. 1985, 107, 2033.
- ¹⁷ Jia, C.; Müller, P.; Mimoun, H. J. Mol. Cat. A: Chem. 1995, 101, 127.
- ¹⁸ Lehman, J.; Lloyd-Jones, G. C. *Tetrahedron* **1995**, *51*, 8863.
- ¹⁹ Pàmies, O.; van Strijdonck, G. P. F.; Diéguez, M.; Deerenberg, S.; Net, G.; Ruiz, A.;
- Claver, C.; Kamer, P. C. J.; van Leeuwen, P. W. N. M. J. Org. Chem. 2001, 66, 8867.
- ²⁰ Pericàs, M. A.; Puigjaner, C.; Riera, A.; Vidal-Ferran, A.; Gómez, M.; Jiménez, F.; Muller, G.; Rocamora, M. *Chem. Eur. J.* **2002**, *8*, 4164.
- ²¹ Janssen, J. P.; Helmchen, G. Tetrahedron Lett. 1997, 38, 8025.